<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473797</url>
  </required_header>
  <id_info>
    <org_study_id>AOM10182</org_study_id>
    <secondary_id>2010-023344-32</secondary_id>
    <nct_id>NCT01473797</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis</brief_title>
  <acronym>ECLA</acronym>
  <official_title>Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Patients With Pulmonary Langerhans Cell Histiocytosis and Impairment of Lung Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ECLA is a phase II, multicenter study testing sub cutaneous cladribine 0.1mg/kg/j during 5
      days, administrated every month for 4 courses, in symptomatic adult patients with pulmonary
      Langerhans cell histiocytosis and impairment of lung function patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ECLA is a phase II, multicenter study testing sub cutaneous cladribine 0.1mg/kg/j during 5
      days, administrated every month for 4 courses, in symptomatic adult patients with pulmonary
      Langerhans cell histiocytosis and impairment of lung function patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulated incidence of response to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>response to treatment after 6 months is defined as
≥10% improvement of forced vital capacity (FVC)
and/or ≥10% improvement of postbronchodilator forced expiratory volume (FEV1) and ≥200ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responses to treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute variations of FEV1, FVC, residual volume (RV), and Diffusing capacity of the lung for carbon monoxide (DLCO), (expressed in mL)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 neutropenia or thrombopenia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 or 4 side effects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment of extra pulmonary localizations of the Langerhans disease</measure>
    <time_frame>6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pneumothorax</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary malignant disease</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of nodular and cystic semiquantitative scores in High Resolution Computed Tomography (HRCT)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Langerhans Cell Histiocytosis of Lung</condition>
  <arm_group>
    <arm_group_label>cladribine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months</description>
    <arm_group_label>cladribine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 55 yr

          -  Histologically proven pulmonary Langerhans cell histiocytosis ( patients with
             presumptive diagnosis whose lung function precludes lung biopsy may be included after
             revision of their medical record at the national reference center for Langerhans cell
             histiocytosis)

          -  Symptomatic pulmonary Langerhans cell histiocytosis (NYHA dyspnea class ≥2) with:

               -  irreversible airflow obstruction (FEV1/FVC&lt;70%) with postbronchodilator FEV1
                  comprised between 30 and 70% of predicted

               -  and/or decrease ≥15% in FEV1, FVC or DLCO as compared to baselines values in the
                  year preceding the inclusion

          -  Signed written informed consent

        Exclusion Criteria:

          -  Women at childbearing age without adequate contraception or wishing breastfeeding

          -  Male without adequate contraception during the study

          -  Dyspnea due to severe pulmonary arterial hypertension (PAP≥35mmHg) confirmed by
             cardiac right catheterism

          -  Previous malignancy

          -  Current infectious disease

          -  Renal failure

          -  Liver failure

          -  Severe alteration of lung

          -  Hematologic disease unrelated to Langerhans cell histiocytosis

          -  Epilepsy

          -  Hepatic, spleen or hematology involvement by Langerhans cell histiocytosis

          -  Pneumothorax within a month previously to inclusion

          -  Previous treatment with cladribine

          -  Contra indication to the use of cladribine

          -  Previous myelosuppressive treatment

          -  Simultaneous participation to another interventional clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdellatif TAZI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Louis hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

